Study cohort n = 25 | |
---|---|
General | |
Age, years | 69 (62–75) |
Male sex, n (%) | 21 (84) |
Hypertension, n (%) | 20 (80) |
Diabetes mellitus, n (%) | 9 (36) |
Family history of CAD, n (%) | 11 (44) |
Current smoking, n (%) | 2 (8) |
Symptoms | |
None | 2 (8) |
Angina | 14 (56) |
Typical angina | 12 (48) |
CCS 1 | – |
CCS 2 | 7 (28) |
CCS 3 and 4 | 5 (20) |
Atypical angina | 2 (8) |
Dyspnea | 9 (36) |
NYHA I | – |
NYHA II | 8 (32) |
NYHA III/IV | 1 (4) |
Known CAD | 12 (48) |
Caffeine consumption and serum levels | |
Coffee, cups | 3 (2–4) |
Tea, cups | 4 (2–4) |
Caffeine level baseline CMR, mg/L | < 1 |
Caffeine level follow-up CMR, mg/L | 4.6 ± 2.3 |
CMR routine parameters | |
LVEF, % | 64 ± 6 |
LVEDVi, mL/m2 | 130 ± 32 |
LVESVi, mL/m2 | 49 ± 19 |
IVS thickness, mm | 13 ± 3 |
LA, cm2 | 21 ± 4 |
Ischemic segments (16-segments model) | 7.4 ± 3.2 |
Days between baseline and follow-up CMR | 12 (3–14) |